Medicare Drug Savings Act of 2017
- Last Action
- 2/1/2017
Actions
- 2017-02-01Read twice and referred to the Committee on Finance.
- 2017-02-01Introduced in Senate
CRS Summary
As of 2017-02-01 (00)
Medicare Drug Savings Act of 2017
This bill requires drug manufacturers to issue rebates to the Centers for Medicare & Medicaid Services (CMS) for prescription drugs dispensed to eligible low-income individuals under the Medicare prescription drug benefit or a Medicare Advantage (MA) prescription drug plan (PDP).
Subject to civil monetary penalties, a Medicare or MA PDP sponsor must report, both to drug manufacturers and to the CMS, specified information related to the determination and payment of such rebates.
Cosponsors (15)
- Patrick Leahy (D-VT)
- Richard Durbin (D-IL)
- Angus King (I-ME)
- John Reed (D-RI)
- Richard Blumenthal (D-CT)
- Sherrod Brown (D-OH)
- Debbie Stabenow (D-MI)
- Bernard Sanders (I-VT)
- Tammy Baldwin (D-WI)
- Mazie Hirono (D-HI)
- TOM UDALL (D-NM)
- Al Franken (D-MN)
- Amy Klobuchar (D-MN)
- Sheldon Whitehouse (D-RI)
- Jeanne Shaheen (D-NH)
Subjects
- Government information and archives
- Health care costs and insurance
- Inflation and prices
- Medicaid
- Medicare
- Prescription drugs
- Public contracts and procurement
- Retail and wholesale trades
Sourced from Congress.gov (public domain).
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.